A Randomised, Single-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, and Pharmacokinetics of Single Rising Doses of BI 3031185 Administered as Tablet to Healthy Male Subjects, and a Randomised, Open-label, Single-dose, Two-way Cross-over Relative Bioavailability Comparison of BI 3031185 as Tablet With and Without Food in Healthy Male Subjects
Latest Information Update: 18 Nov 2024
At a glance
- Drugs BI 3031185 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 19 Sep 2024 Status changed from active, no longer recruiting to completed.
- 23 Jul 2024 Status changed from recruiting to active, no longer recruiting.
- 27 May 2024 Planned End Date changed from 9 Jul 2024 to 26 Aug 2024.